SGMO vs ANRO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ANRO Captures Institutional Edge (3โ1 Pillars ยท 5โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Alto Neuroscience Inc. (ANRO) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while SGMO counters with relative strength in Valuation. Fundamentally, SGMO trades at 0.4x Forward P/E with -175.5% operating margin (+88.4% YoY revenue) versus ANRO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, SGMO sits in UNCLASSIFIED (71st %ile IV; Dealer Gamma Walls on Pro) against ANRO sits in CONSOLIDATION (8th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SGMO | ANRO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $55.9M | $1.2B | Larger Scale | ANRO |
| Trailing P/E Ratio Valuation | 0.4x | N/M | Lower Multiple | SGMO |
| Forward P/E Ratio Valuation | 0.4x | N/M | Lower Multiple | SGMO |
| Revenue Growth (YoY) Growth | +88.4% | +0.0% | Higher Growth | SGMO |
| Operating Margin (TTM) Profitability | -175.5% | 0.0% | Higher Margin | ANRO |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -2891.8% | -46.7% | Higher ROE | ANRO |
| 52-Week Range Position Momentum | 9% ($0โ$1) | 64% ($11โ$37) | Stronger Trend | ANRO |
| Beta / 30D Volatility Risk Regime | 1.49ฮฒ ยท 206% Vol | 1.95ฮฒ ยท 89% Vol | Lower Realized Risk | ANRO |
| Unified Institutional Score Composite Signal | 52.0 / 100 (HOLD) | 29.3 / 100 (SELL) | Higher Composite | SGMO |